WTB
LRMR icon

Washington Trust Bank’s Larimar Therapeutics LRMR Stock Holding History

Washington Trust Bank’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25
Closed -$2K – 793
2015
Q4 		$2K Buy
+25
New +$4.02K ﹤0.01% 700

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Washington Trust Bank's LRMR Position: Q1 2016 in Review

Washington Trust Bank sold out of Larimar Therapeutics (LRMR) in Q1 2016, closing a stake of 25 shares — an estimated $2K sold.

Washington Trust Bank first reported a position in LRMR in Q4 2015 and held it in 1 quarter. The position peaked at $2K in Q4 2015. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2016.

  • Washington Trust Bank reported no remaining Larimar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Washington Trust Bank sold 25 Larimar Therapeutics shares in Q1 2016, an estimated $2K.
  • Washington Trust Bank first reported a position in Larimar Therapeutics in Q4 2015 and held it in 1 quarter.
  • Washington Trust Bank's Larimar Therapeutics position peaked at $2K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2016.

Based on Washington Trust Bank's 13F filing for Q1 2016, filed 25 Apr 2016.